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Abbreviations 
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HDFs: Human Dermal Fibroblasts 
CAFs: Cancer Associated Fibroblasts 
ROS: Reactive Oxygen Species 
UVA: Ultra Violet A 
RCA/CCP: Regulators of Complement Activation/ Complement Control 
Proteins. 
 
Abstract  
CSL is a key transcriptional repressor and mediator of Notch signaling. 
Despite wide interest in CSL, mechanisms responsible for its own regulation 
are little studied. CSL down-modulation in human dermal fibroblasts (HDFs) 
leads to conversion into cancer associated fibroblasts (CAF), promoting 
keratinocyte tumors. We show here that CSL transcript levels differ among 
HDF strains from different individuals, with negative correlation with genes 
involved in DNA damage/repair. CSL expression is negatively regulated by 
stress/DNA damage caused by UVA, Reactive Oxygen Species (ROS), 
smoke extract, and doxorubicin treatment. P53, a key effector of the DNA 
damage response, negatively controls CSL gene transcription, through 
suppression of CSL promoter activity and, indirectly, by increased p21 
expression. CSL was previously shown to bind p53 suppressing its activity. 
The present findings indicate that p53, in turn, decreases CSL expression, 
which can serve to enhance p53 activity in acute DNA damage response of 
cells. 
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Introduction 
 CSL (CBF1, SUH, Lag1, also known as RBPJκ) is a highly conserved 
transcription factor with both Notch dependent and independent roles. 1 This 
DNA binding protein is endowed with intrisic transcription repressive function, 
and is converted into an activator of transcription by association with the 
proteolytically cleaved activated forms of Notch receptors. CSL binds to 
regulatory regions of target genes in a dynamic and cell-type specific manner, 
and genes to which it binds with high affinity can be similarly induced by CSL 
down-modulation and Notch activation. 1 We have recently showed that CSL 
expression in dermal fibroblasts is key for skin homeostasis, and that its 
down-modulation results in a cancer-inducing stromal environment. 2 Loss of 
CSL gene function leads to the conversion of dermal fibroblasts into cells with 
cancer associated fibroblast (CAF) properties, with subsequent recruitment of 
inflammatory cells and establishment of « cancer fields », with expanding 
premalignant and malignant keratinocytic lesions. 2, 3 The in vivo significance 
of these findings is supported by the fact that CSL is less expressed in 
stromal fibroblasts of premalignant and malignant skin SCC lesions relative to 
surrounding normal skin. 4 However, the mechanisms involved in CSL down-
regulation remain to be investigated. 
 Surprisingly little is known on control of CSL gene expression. The 
Notch pathway is built on a series of positive and negative feedback loops 
often operating in a cell type-specific manner. 5 This complex mode of 
regulation results from convergent and reciprocal control of expression of the 
canonical components: Notch ligands, Notch receptors, CSL, and 
transcriptional repressors of the Hes/Hey family, as well as co-factors like 
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MAML proteins. 5 The Drosophila melanogaster and Caenorhabditis elegans 
homologs of CSL, Suppressor of Hairless (SuH) and LAG-1 respectively, can 
either activate or repress their own expression, determining cell fate. 6, 7 Little 
else is known of control mechanisms of CSL gene transcription. At the protein 
level, other pathways converge on control of its function. For instance, in 
mammalian cells Wnt signaling can inhibit CSL activity by direct binding of 
Dishevelled, and CSL stability is regulated by Presenilin-2 and p38 MAP-
kinase, while its cellular localization can be regulated in Xenopus laevis or 
mammalian cells by RITA  or SMRT protein complexes. 8-11 
 Recent advances in human genomic and transcriptomic analyses 
provide insights into individual differences in susceptibility to disease, with 
tissue-specific control of gene expression as key determinant. 12 For novel 
insights into control of CSL gene expression, we started from the study of 
individual variations in gene expression in human dermal fibroblasts (HDFs) 
derived from many different individuals. Gene ontology analysis of co-
regulated genes pointed to the DNA damage / stress response as a possible 
negative regulator of CSL expression, which we experimentally assessed in 
HDFs upon various treatments. Importantly, we found that p53, a key element 
in the DNA damage / stress response, is involved in negative control of CSL 
transcription by direct binding to the CSL gene and/or through its effector p21. 
The Notch and p53 pathways interact at multiple levels, in a context 
dependent manner. 13 We recently uncovered that, in HDFs, CSL functions as 
a direct negative regulator of p53 activity and that induction of p53-dependent 
cellular senescence provides a fail-safe mechanism against the 
consequences of compromised CSL activity. 4 The present findings indicate 
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that p53, in turn, represses CSL transcription, which can serve to enhance 
p53 activity in the acute response of cells to DNA damaging cancer-
threatening conditions. 
 
Results 
1) Individual variations in Notch/CSL signaling genes 
Substantial differences can exist in levels of gene expression among cells 
from different individuals that are key to understand variations in susceptibility 
to disease. 12 As mentioned, CSL plays an important role in dermal fibroblasts 
as negative regulator of senescence and CAF activation. 2, 4 To probe into 
individual variations in expression of CSL and related genes, we undertook 
RNA sequencing analysis of second passage HDFs derived from 46 healthy 
individuals (GSE77371 and Supplementary Table 1). RNA sequencing reads 
showed that, besides CSL (Fig. 1A), several components of the Notch family 
are expressed at significant levels in HDFs, with NOTCH2 being more highly 
expressed than NOTCH1 as we previously reported 2 (Fig. 1B). Among Notch 
ligands, JAG1 expression was greater than DLL1 (paired t-test p < 0.0001), 
while JAG2, DLL2 and DLL4 expression was not detectable (Fig. 1C). Among 
canonical Notch/CSL targets, HES4 was more expressed than HES1 or HES6 
(paired t-test p < 0.0001), with HES1 being expressed only in some strains 
(38/46) (Fig. 1D). Comparative RT-qPCR and RNA-seq analysis of lowly 
expressed genes like DLL1 in a selected set of samples showed comparable 
individual variations (Fig. 1E). CSL expression was modulated around a 
RPKM average of 9.8, with higher levels being found in some HDF strains and 
lower in others (CV, coefficient of variation of 0.26) (Fig. 1A). Two other 
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genes, NOTCH3 and JAG1, showed high heterogeneity of expression among 
the various strains (CV > 0.6), while NOTCH2 was highly expressed in all, 
with very little variation (CV = 0.15) (Fig. 1B, C). 
 Notch signaling components have the potential of controlling each 
other’s expression in either a positive or negative fashion. 5, 14 Correlation 
analysis of RNA-seq data showed that CSL levels among various cell strains 
were inversely regulated with those of NOTCH1, consistent with CSL 
functioning as a repressor of this gene 5, while CSL expression was positively 
correlated with DLL1 and TLE1, suggesting common control mechanisms 
(Fig. 1F). Interestingly, a trend of positive and negative correlation between 
expression of CSL and other Notch signaling components was also observed 
(Fig. 1F). Although not statistically significant, this was confirmed by RT-qPCR 
(Fig. 1G). Among the inversely related genes we note HES1, which we 
previously showed to be up-regulated in HDFs by CSL silencing. 5 
 
2) Identification of CSL-coregulated genes 
 We recently showed that down-modulation of CSL expression leads to 
fibroblast senescence, with the concomitant induction of a CAF phenotype. 4 
Consistent with these findings, CSL expression was overall inversely 
correlated to that of CAF effector genes with WNT3, PKM and NGF showing 
the best Pearson scores (p< 0.005) (Fig. 1H). 
 For more general insights into CSL regulation and function, we 
broadened our analysis of the RNA-seq profiles for identification of all genes 
significantly correlated with CSL in either a positive or negative manner. 
Expression of 466 genes was positively correlated with that of CSL across the 
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46 strains, (Pearson score > 0.5, p < 0.0005), while 576 genes were 
negatively correlated (Pearson score < -0.5, p < 0.0005) (Fig. 1I and 
Supplementary Table 2). Gene ontology and pathway analysis showed that 
genes positively correlated with CSL expression were enriched for families 
related to complement system, proliferation, blood vessel morphogenesis and 
suppression of apoptosis (via NF-κB). By contrast, oppositely correlated 
genes were enriched for families related to cytoskeleton and cell adhesion, 
mitosis and meiosis, epithelial-to-mesenchymal transition and development, 
protein folding and DNA damage. Among CSL positively or negatively 
correlated genes many were transcription factors, as shown in Fig. 1J. For 
further studies on a possible connection between CSL expression and these 
various cellular functions, we focused on DNA damage response. 
 
3) Stress / DNA damaging conditions as negative regulators of CSL 
expression 
 Intrigued by the possibility that DNA damage as a consequence of 
stress could regulate CSL levels, we assessed levels of CSL expression in 
various HDF strains upon exposure to UVA, the form of UV light with higher 
penetration power, capable of reaching the dermal compartment of the skin 
and directly affecting dermal fibroblasts. 15 RT-qPCR analysis showed that 
CSL expression was down-modulated in all tested HDF strains at various 
times after UVA exposure, with CDKN1A being oppositely regulated (Fig. 2A, 
B).  
 UVA is a major cause of skin photoaging and cancer, with production 
of reactive oxygen species (ROS) as main mediator of its effects, including 
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those on the DNA. 16 As with UVA, CSL down-modulation and CDKN1A up-
regulation were observed upon treatment of several HDF strains with glucose 
oxidase, which results in continuous production of ROS via oxidation of 
glucose in gluconolactone and hydrogen peroxide 17 (Fig. 2C). Similar results 
were observed after treating cells with extracts of cigarette smoke, another 
potent inducer of oxidative stress – as well as DNA damage 18 (Fig. 2D). 
Chemotherapeutic DNA-damaging agents have also been reported to cause 
stromal fibroblasts senescence and CAF activation. 19 As in response to the 
other insults, treatment with doxorubicin resulted in down-regulation of CSL 
and opposite CDKN1A induction (Fig. 2E). 
 
4) p53 as a negative regulator of  CSL expression. 
 The opposite regulation of CSL and CDKN1A expression in response 
to several stress/DNA damaging conditions suggested that p53 may be 
involved. To directly assess whether p53 functions as a negative regulator of 
CSL expression, HDFs were stably infected with a lentivirus for inducible p53 
expression. As shown in Fig. 3A and B, induction of wild-type p53 resulted in 
consistent down-regulation of CSL, at both RNA and protein levels, in all 
tested HDF strains. No such effects were observed after similar expression of 
a DNA binding domain p53 mutant protein (R248W) (Fig. 3A, B). 
 As an alternative approach, HDFs were treated with Nutlin-3a, a MDM2 
inhibitor and inducer of endogenous p53 activity through p53 protein 
stabilization. Even in this case, CSL expression was consistently down-
regulated in all tested strains (Fig. 3C, D). A detailed time course after Nutlin-
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3a treatment showed p53 accumulation and concomitant induction of p21 (as 
a read-out for p53 activation) preceding CSL down-modulation (Fig. 3E, F). 
 Mirroring these results, p53 silencing in several strains of HDFs led to a 
significant induction of CSL expression both at RNA and protein levels (Fig. 
3G, H). 
 
5) Multiple mechanisms of negative control of CSL expression by p53 
 One mechanism whereby p53 can negatively control expression of 
target genes is through direct weak binding to their regulatory regions. 20 The 
CSL locus encompasses more than 150 kb. Bioinformatic analysis (with 
MatInspector, Genomatix) of the enhancer and promoter regions (identified on 
the basis of the human primary fibroblasts data in the ENCODE database) 
(Fig. 4A) revealed the presence of 144 putative binding sites for p53. To 
assess whether p53 binds to any of these, we performed ChIP-seq (ChIP 
combined with massive parallel DNA sequencing) analysis of HDFs under 
basal conditions and after p53 stabilization by Nutlin-3a treatment (Fig. 4B) 
(GSE77371). As a positive p53 target, we analyzed the CDKN1A locus and 
found, as expected, 3 regions of p53 strong binding under basal conditions, 
with 2 additional binding peaks in Nutlin-3a treated cells (Fig. 4B, upper panel 
and Supplementary Table 3). By contrast, at the CSL locus, we found a single 
p53 binding peak, only in the Nutlin-3a treated cells (Fig. 4B, middle panel 
and Supplementary Table 3). This was located in intron 4 of the CSL gene, a 
position outside of predicted regulatory regions and consistent with the one 
found in a previous survey of p53 binding sites in IMR90 lung fibroblasts 21 
(Data accessible at NCBI’s GEO database 22, accession GSE31558). The 
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binding peak enrichment for p53 at the CSL locus was lower than those at the 
CDKN1A locus but comparable to the one we found at the PTK2 (Fak kinase) 
gene (Fig. 4B, lower panel and Supplementary Table 3), a previously reported 
gene under direct negative p53 control. 23, 24  
 Despite the lack of ChIP-seq p53 binding peaks in regulatory regions of 
the CSL locus, weaker p53 binding cannot be ruled out due to the relatively 
low sensitivity of the method. Sequence analysis of the CSL promoter region 
(chr4: 26320712–26322647) revealed the presence of three predicted p53 
binding sites, two clustered upstream of the transcription start site (BS1 and 
BS2) and the other in the first intronic region (BS3) (Fig. 4C, top panel). These 
sites have various mismatches relative to the consensus p53 recognition 
sequence, which may result in a low binding affinity. 25, 26 In fact, direct 
chromatin immunoprecipitation (ChIP) assays showed only weak p53 binding 
to these sites, in Nutlin-3a treated HDFs, in contrast to the more significant 
binding to the intron 4 region of the CSL gene or the CDKN1A promoter (Fig. 
4C, bottom panel). 
 Bioinformatic analysis of genomic variations in the human population 
showed the presence of a single nucleotide polymorphism (SNP; rs7657866) 
that abrogates the predicted p53 recognition sequence of the BS3 site in the 
CSL promoter (as determined by MatInspector, Genomatix). The minor 
nucleotide allele (A) is present in a homozygous form in 8.42% of the human 
population and in 33,2% in heterozygous form with the major allele (G). In our 
collection of HDF strains, by direct nucleotide sequencing we found three 
strains with the A/A genotype. Modulation of endogenous CSL expression in 
these strains in response to Nutlin 3-a treatment was not consistently different 
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from that of strains harboring the major allele. To directly assess whether p53 
can negatively control CSL promoter activity and whether in this context the 
identified SNP is of functional significance, we cloned the CSL promoter 
spanning this region from cells homozygous for both the G/G and A/A alleles. 
As shown in Fig. 4D, activity of the CSL promoter with the major G/G allele 
(CSLpr-1.94kb G/G) was effectively suppressed by p53 in a dose-dependent 
manner. Activity of the CSL promoter with the minor A/A allele was 
differentially suppressed by p53, requiring higher concentrations (Fig. 4D). 
 Besides direct binding to negative target genes, another 
complementary mechanism by which p53 can negatively control gene 
expression is through one of its effectors, CDKN1A (p21). 27 To assess 
whether increased p21 levels reproduce the effects of p53 activation on CSL 
gene transcription, HDFs were infected with a lentivirus expressing p21. As 
shown in Fig.4E and F, increased p21 levels resulted in suppression of CSL 
expression, similarly to what we observed after induction of p53 expression.  
 
Discussion 
 
 Gene expression can vary significantly between individuals, possibly 
accounting for different susceptibility to complex trait diseases like cancer. 28 
CSL functions in stromal fibroblasts as direct repressor of senescence and 
CAF-determinant genes, and down-modulation of CSL expression is a key 
step for CAF conversion. 4 An important question is therefore how this gene is 
controlled. CSL is best known for its role as key effector of canonical Notch 
signaling. However, the negative correlation between CSL and Notch1 
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expression in primary fibroblasts derived from a large number of individuals 
suggests that the two genes play a separate and possibly opposite function in 
these cells. Gene ontology analysis revealed that among gene families 
negatively correlated with CSL expression several were involved in 
cytoskeleton rearrangements, known to be a feature of myofibroblasts and 
CAF activation. 29, 30 On the other hand, the top positively correlated genes 
were involved in the complement system, with a predominance of RCA/CCP 
(regulators of complement activation/ complement control proteins) genes, 
such as Factor H, C1 inhibitor and MCP. The role of the complement system 
in cancer has long been debated 31: on one hand, complement is thought to 
be supportive of the immune-mediated killing of tumor cells. On the other 
hand, complement activation promotes inflammation, which is correlated with 
tumor onset and progression. 32 The “complement” genes that we found to be 
positively correlated with CSL are negative regulators of complement 
activation. This arises the exciting possibility that an important element of CAF 
conversion resulting from compromised CSL is complement activation, which 
provides an inflammatory tumor-inducing environment. 33 Variations in CSL 
expression levels correlated significantly also with a large number of genes 
that may be both downstream CSL targets and/or upstream regulators. 
Among the first category are likely genes involved in CAF determination, 
coding for a number of growth factors / cytokines as well as determinants of 
cytoskeleton organization and cell motility. Among the second category of 
genes are likely those involved in the DNA damage/stress response.  
 A number of exogenous insults leading to direct or indirect DNA 
damage, such as UVA irradiation, exposure to Reactive Oxygen Species 
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(ROS), smoke extracts and doxorubicin, caused down-modulation of CSL 
expression in the tested fibroblast strains. UVA is thought be an important 
etiological factor of skin photo-aging and cancer 15, 34 and, due to its great 
penetration power, it can directly affect the dermal compartment of the skin. 
Its effects are mostly mediated by the enhanced production of Reactive 
Oxygen Species (ROS), which cause secondary DNA damage as well as 
changes in many other aspects of cell physiology. 35 Cigarette smoke extract, 
another stress inducer, is composed by several toxic compounds, such as 
nicotine and hydrogen monoxide, which target directly or indirectly the DNA 
and induce fibroblast senescence and CAF activation. 18 Doxorubicin, a 
chemotherapeutic DNA damaging agent, also causes stromal fibroblast 
senescence and CAF activation. 19 All these stress conditions resulted in 
significant down-modulation of CSL expression with concomitant induction of 
CDKN1A levels, a common indicator of p53 activity. While we focused on p53 
for further studies, UVA exposure represses CSL expression also in HDFs 
with p53 gene silencing (Supplementary Fig. 1A, B), indicating that other 
determinants of the DNA damage / stress response converge on negative 
regulation of this gene. A possible mechanism is promoter DNA methylation, 
as CSL expression is down-modulated with the same kinetics of Notch2 
(Supplementary Fig. 1C), whose down-modulation upon UVA treatment is due 
to DNA methylation. 2 
 The transcriptional repressing function of p53 is relatively poorly 
understood. 36 It can be mediated, in part, by direct p53 binding to target 
genes. It has been proposed that the p53 consensus recognition sequences 
of induced and repressed genes are different, with validated repressor sites 
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having a weaker affinity with longer spacers between quarter-sites and/or 
changed orientation of these sites. 26 We identified a specific site within the 
CSL locus in intron 4, to which p53, at enhanced levels, binds. However, this 
site has a complete p53 responsive element with a theoretical high 
transactivation score and lies outside any predicted regulatory regions of the 
CSL gene, making it unlikely to be involved in negative control of its 
expression. More functionally relevant is likely to be the ability of p53 to 
negatively control CSL promoter activity. Indeed we show that CSL promoter 
activity is suppressed in exogenous assays by increased p53 in a dose 
dependent manner, with lesser inhibition resulting from a nucleotide 
polymorphism in the CSL promoter abrogating a p53 recognition sequence.  
 Another mechanism by which p53 can negatively control gene 
transcription is through one or more of its effectors, such as p21 (CDKN1A). 
p21 can function as a negative regulator of gene expression, independently of 
its effects on the cell cycle, through a variety of mechanisms including binding 
and negative regulation of E2F1 activity 27, 37-39, recruitment of E2F4 
repression complexes 37, and binding and modulation of Estrogen Receptor 
alpha –dependent transcription. 40 The impact of increased or decreased p21 
activity in stromal fibroblasts remains to be conclusively established, as it has 
been variously reported that p21 overexpression induces CAF conversion 41 
or only cellular senescence without induction of the senescence-associated 
CAF-related secretory phenotype. 42 In our own work, we found that silencing 
of the p21 gene, like that of p53, can synergize with CSL knockdown in 
induction of CAF marker expression 4, pointing to an overlap of p53 and p21 
transcription repressive function beyond control of the CSL gene.  
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 Overall, an emerging scenario exists of a reciprocal negative feedback 
loop between p53 and CSL activity, which could be responsible for overriding 
individual differences in gene expression, allowing a proper response to 
stress factors and thus maintaining stromal tissue homeostasis. We recently 
showed that CSL directly binds to p53 suppressing its activity and, as part of 
the chronic process leading to cancer development, p53-induced senescence 
can function as fail-safe mechanism against cancer/stromal cell expansion 
resulting from compromised CSL function. 4 In turn, the present findings 
indicate that p53 negatively controls CSL expression, thus providing a positive 
feedback mechanism for enforcement of p53 activity in the acute response of 
cells to DNA damaging cancer-threatening conditions (Fig. 4G). 
 
Materials and methods 
 
Human samples and cell culture 
Discarded human foreskin tissue samples for primary cell preparation were 
obtained from the Department of Pediatrics, Lausanne University Hospital, 
with institutional approvals and informed consent as part of institutional 
requirements. 
Conditions for culturing of cells, viral infection, siRNA-mediated gene 
silencing, RT–qPCR and ChIP were as previously reported. 2, 43, 44 For 
derivation of HDFs, surgically excised foreskins were fragmented into pieces 
after removal of the hypodermis, followed by incubation in 1% collagenase I 
solution at 37°C under shaking. The dissociated tissue was diluted, filtered 
and washed by centrifugation and subsequently cultured in 10% FBS DMEM 
without Phenol Red (Gibco), in order to avoid any absorbance of UV light by 
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the medium. For stress inducing experiments, cells were treated when they 
reached 60% confluence. UVA irradiation (1J/cm2) was performed in a UVA 
irradiator (Vilber) monitored with a dosimeter (InternationaLight.Inc). 
Chemicals used for the study were as follows: 20 mU/ml of glucose oxidase 
(Sigma), 50 μg/ml of Cigarette Smoke Extract (Murty Pharmaceuticals), 0.4 
μM of doxorubicin hydrochloride (Sigma), 10 μM of Nutlin-3a (Sigma) or 
suitable controls. Doxycycline hyclate (Sigma) was used at a dose of 750 
ng/ml at the indicated time in experiments with cells transduced with 
lentiviruses for doxycline-inducible expression. 
 
RT-qPCR and immunoblotting 
RT–qPCR were carried out as previously described 4 in triplicate using the 
following primers:  36β4 Fwd: 5’-GCAATGTTGCCAGTGTCTGT-3’, Rev: 5’-
GCCTTGACCTTTTCAGCAAG-3’; CSL Fwd: 5’-
GGCTGGAATACAAGTTGAACA-3’,  Rev: 5’-AGAGCAAAAGCTCAAAGGTG-
3’; p21 Fwd: 5’-AGCAGAGGAAGACCATGTGGACCT-3’, Rev: 5’-
GAAGATGTAGAGCGGGCCTTTGAGG-3’. Immunoblotting experiments were 
carried out as previously described 4 using the following antibodies: for CSL, 
D10A4 (Cell Signaling), for p53, sc-126 (Santa Cruz Biotechnology) and for γ-
tubulin, clone GTU-88 (Sigma). 20 μg of proteins were loaded on 10% 
acrylamide gels, and detection was performed using the infrared fluorescent 
IRDye® secondary antibodies (LI-COR®) and the Odissey CLx (LI-COR®) 
infrared imaging system. Image analysis were performed using the Image 
Studio software (LICOR®). 
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Plasmids and siRNAs 
To make the pIND20-p53WT and pIND20-p53R248W plasmids, PCR 
products using the primers Fwd: 5’-
CACCATGGAGGAGCCGCAGTCAGATCCTAGCGTCGA-3’ and Rev: 5’-
TCAGTCTGAGTCAGGCCCTTCTGTCTTGAA-3’ and pBABE-puro-p53WT 
and pBABE-puro-p53R248W vectors as respective templates (obtained from 
Dr A. Rustgi, University of Pennsylvania, PA 45), were cloned into the pENTR-
D-TOPO entry vector (Life Technologies) and transferred through the 
Gateway LR Clonase system (Life Technologies) into the pINDUCER20 
destination vector 46 using the pENTRTM directional TOPO cloning kit. The 
same strategy was used to produce pIND20-CSL, using the following PCR 
primers Fwd: 5’-
CACCATGGACCACACGGAGGGCTCGCCCGCGGAGGAGCC-3’ and Rev: 
5’-TTAGGATACCACTGTGGCTGTAGATGATGTGAC-3’. with pBMNRBPj 
plasmid 47 as template. The pIND20-p21 was obtained from Dr SJ Elledge 
(Brigham and Women's Hospital, Boston, MA) 46. The pRS-p53 (shp53) and 
control pRS vectors were obtained from Dr. R. Agami (The Netherlands 
Cancer Institute, Amsterdam, The Netherlands). 
 
RNAseq analysis 
Total RNAs from HDFs were extracted using the directZol RNA miniprep kit 
(Zymo Research) with on-column DNase treatment. RNA quality was verified 
on the Bioanalyzer (Agilent) and 1 µg of total RNA with RIN> 8 was used for 
library preparation using the NEBNext® Ultra kit (NEB) according to 
manufacturer instructions. Single read was done on the Illumina HiSeq 2000 
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sequencer at the Genomic Technologies Facility (University of Lausanne). 
Sequencing quality check was performed using FastQC (v 0.10.1 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). PolyA tails, 
adapter sequences and low quality reads were cut using Cutadapt 48 (v 1.4.1), 
using a base quality cutoff of 5. The alignment was performed using Tophat2 
49 (v 2.0.9) and GRCh37 as reference genome. Reads were sorted by position 
in the reference genome using Picard (http://broadinstitute.github.io/picard/ v 
1.96). Indexing was performed using sambamba 
(http://lomereiter.github.io/sambamba/ v 0.4.7) and alignment statistics using 
bamtool stats (http://sourceforge.net/projects/bamtools/ v 2.3.0). RNAseq 
quality was checked using the R package NOISeq50 (v 2.6.0), analyzing 
coverage, percentage of reads mapping to different genes and fraction of 
rRNA. Reads were counted and gene expression evaluated using HTSeq (v 
0.6.1).  
Data have been deposited in NCBI’s Gene Expression Omnibus 22 and are 
accessible through GEO series accession number GSE77370 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77370). 
 
Bioinformatic analyses 
The graphic illustrations showing the correlation analysis between various 
genes and CSL were produced using the R package corrplots (v 0.73), 
starting from the RNAseq RPKM reads. Correlation analyses were performed 
on the matrix of log2 RPKM values for the 46 foreskin samples after combat 
algorithm to adjust data for batch effect 51. Genes with Pearson coefficient > 
0.5 and p < 0.0005 were considered as significantly correlated to CSL. 
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Correlation matrices were generated in R using the cor() function. The corrplot 
package was then used to graphically display correlation matrices. The 
functional annotation tool available within DAVID Website 
(http://david.abcc.ncifcrf.gov/) was used to look for any over-represented 
biological process level 5 (BP5) of the Gene Ontology (GO). Process 
networks and pathway maps analysis was performed with MetaCoreTM 
version 6.2 (Thomson Reuters). 
 
Locus analysis, ChIP assay and ChIP-seq 
For human CSL locus analysis, we used ENCODE data 
(http://genome.ucsc.edu/ENCODE) giving information on chromatin 
organization. Based on the Chromatin in State Segmentation by HMM data, 
we defined promoters and enhancers in the CSL locus. Exons were defined 
taking in account all exons described for the four main CSL transcript variants 
described in the NCBI database. The variants analyzed are: NM_005349.3, 
NM_203283.2, NM_015874.4, NM_203284.2. 
ChIP assays with antibodies against p53 versus non-immune IgG control 
were carried out as previously described 4 followed by determination of 
binding enrichment for the indicated sites; primer sequences were as follows: 
CDKN1Apr_BSF: 5’-TGGACTGGGCACTCTTGTC-3’, CDKN1Apr_BSR: 5’-
AGAAAGCCAATCAGAGCCAC-3’, negativeCTRL_BSF: 5’-
CCCTAATGGTCTAAAAAGGG-3’, negativeCTRL_BSR: 5’-
ACTACCACTTACAGTGCCTG-3’, CSLintron4_BSF: 5’-
TTTCCAAATAAGGAAGGGGC-3’, CSLintron4_BSR: 5’-
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CTCTAAAGCCTCCTATCAAC-3’. CSLpr_BS1.2F: 5’-
GGCGCCCGGAGCTGGT-3’ CSLpr_BS1.2R: 5’- 
TGGGAAATTTCCTAAACCTCG-3’ CSLpr_BS3F: 5’- 
AAGGGCCTCCTCATTAGCAT-3’ CSLpr_BS3R: 5’- 
TAATCTCGGCGTTTGGTGCA-3’. CDKN1Apr_BS primers were used as a 
positive control for binding of p53 to the CDKN1A promoter. 
negativeCTRL_BS were primers designed for a putative p53 binding site in 
the enhancer of CSL, which was not confirmed, and were used as a negative 
control for p53 binding. 
For ChIP-seq analysis, immunoprecipitated DNA from HDFs was processed 
as for ChIP assays 4 using 5 μg of antibody against p53 per 106 cells. The 
ChIPed DNA was quantified by fluorimetry on a Qubit system (Invitrogen). A 
total of 10 ng of DNA was used for library preparation using a NEBNext ChIP-
Seq Library Prep reagent set (New England Biolabs Inc.), as recommended 
by the manufacturer. The sequencing was performed by the Genomic 
Technologies Facility at Lausanne University. Sequencing quality control was 
performed using FASTqc 52; immunoprecipitation quality control was 
performed using PhantomPeak 53 quality tools and CHANCE 54. Burrows–
Wheeler Aligner 55  was used for FASTQ file alignments and, for peak 
detection, MACS software 56 with default parameters was used. Each peak 
was associated to the closest transcription starting sites with ChIPpeakAnno 
57, a Bioconductor R package. The Integrative Genomics Viewer (IGV) 
(http://www.broadinstitute.org/igv) was used for graphic illustration of ChIP-
Seq peaks, and ENCODE data (http://genome.ucsc.edu/ENCODE) for 
information on chromatin organization. ChIP-Seq data have been deposited in 
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NCBI’s Gene Expression Omnibus 22 and are accessible through GEO series 
accession number GSE77225 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77225). 
For SNP analysis, the 1000 genome database was used in the SPSmart 
program (http://spsmart.cesga.es). 
 
Promoter activity assay 
The CSL promoter-1.94 kb vector (CSLpr-1.94kb) (chr4: 26,320,712–
26,322,647) was obtained by amplification of the PCR product using the 
following primers Fwd- 5’AGACTAGGTGACTCAAGGCA-3’ and Rev- 5’-
CCACAAACTCTCGCCAAAAC-3’ and human genomic DNA as template. The 
PCR fragment was inserted into the pGL3-enhancer vector (Promega, Firefly 
luciferase) in the BglII/XhoI site and sequence was verified by DNA 
sequencing. HDFs were co-transfected in triplicate with the CSLpr-1.94kb 
(0.5 μg/well) together with the indicated amounts of pBABE-p53WT plasmid 
(obtained from Dr A. Rustgi (University of Pennsylvania, PA)45) as well as 
0.05 ug of the phRL-TK plasmid (Promega, Renilla luciferase for internal 
control). Luciferase activity was determined with the Dual Luciferase assay kit 
(Promega) 30 hours later, using internal Renilla control for normalization. 
 
Statistical analysis 
Two-tailed Student’s t-tests were performed where appropriate unless 
specified. Error bars represent SD. P values are as indicated in figure 
legends. 
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Supplementary Materials 
Supplementary Table 1. RPKM values from RNAseq analysis for each HDF 
strain. 
Supplementary Table 2. List of genes whose expression is positively or 
negatively correlated to CSL plus gene ontology analyses as determined in 
Figure 1 (related to Figure 1I and J). 
Supplementary Table 3. Genomic coordinates of p53 binding peaks in CSL, 
CDKN1A and PTK genes, as revealed by ChIP-seq analysis in HDFs (related 
to Figure 4A-C). 
Supplementary Figure 1. P53 is not the main effector of UVA-induced CSL 
down-regulation. 
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Figure legends 
Fig. 1. Individual variations in gene expression in HDFs. (A-D) Second 
passage HDFs from 48 different individuals were analyzed by RNA 
sequencing. Shown are RPKM (reads per kilobase transcriptome per million 
mapped reads) values for the indicated genes (See also Supplementary Table 
1). (E) Comparison of DLL1 RNA expression levels obtained by RNA 
sequencing versus RT-qPCR analysis. (F) Graphic illustrations of Pearson’s R 
correlation analysis carried out on log2 RPKM values from RNAseq data used 
in A-D, for indicated Notch signaling pathway components against each other 
or against CSL. Blue and red squares correspond to positive and negative 
values respectively. Significant correlation (|Pearson score| > 0.5) is indicated 
in the colorimetric scale as green stars. (G) Comparative correlation analysis 
as performed in F between CSL and Notch signaling genes was determined 
from either RNA-seq or RT-qPCR data. (H) Same analysis as in F was 
performed between CAF markers genes (selected from a previously published 
list 4) against each other and against CSL. (I) The global set of RNA-seq data 
used in A-D was analyzed for positive (in blue) or negative (in red) correlation 
to CSL (|Pearson score| > 0.5, p < 0.0005). The list of genes in each group is 
given in Supplementary Table 2. Gene ontology (Metacore Networks) analysis 
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with statistically significant enrichment (p < 0.05) was performed on genes 
whose expression is positively (left panel) or negatively (right panel) 
correlated to CSL levels. (J) Shown are genes encoding proteins with 
transcription factor activity positively (blue) or negatively (red) correlated to 
CSL selected from Supplementary Table 2.  
 
Fig. 2. Genotoxic and oxidative stresses negatively regulate CSL 
expression in HDFs. (A-B) Indicated strains of HDFs were irradiated with 
1J/cm2 UVA, collected at the indicated time points and CSL (A) and CDKN1A 
(B) mRNA levels were measured by RT-qPCR using 36β4 for normalization. 
N= 5 different experiments for Fb79 and 2 for all other strains. (C) Indicated 
strains of HDFs were treated with 20 mU/ml glucose oxidase for 4 hours, and 
CSL and CDKN1A mRNA levels were measured by RT-qPCR as in A. N= 2 
different experiments for each strain. (D) HDFs (strain Fb79) were treated with 
50 μg/ml of Cigarette Smoke Extract for 48 hours and assessed as in A for 
CSL and CDKN1A mRNA levels. N= 2 different experiments. (E) HDFs (strain 
Fb79) were treated with doxorubicin (0.4 μM) for 24 hours and assessed as in 
A for CSL and CDKN1A mRNA levels. N= 2 different experiments. * p < 
0.0001, ** p = 0.0008. 
 
Fig. 3. p53 is a negative regulator of CSL expression. (A) HDFs stably 
infected with lentiviruses for doxycycline-inducible expression of either wild- 
type p53 (WTp53) or a R248W mutant p53 (mutp53) versus empty vector 
(CTRL) were treated with doxycycline (Dox) for 48 hours. CSL mRNA levels 
were measured by RT-qPCR using 36β4 for normalization. N=2 different 
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experiments for each strain. (B) Indicated HDF strains were treated as in A, 
and CSL and p53 protein levels were assessed by immunoblot analysis using 
γ-tubulin as equal loading control. P53, CSL and γ-tubulin blots were 
performed by sequential blotting of the same membrane without stripping (left 
panel). Relative protein levels were quantified using the ImageStudio 
program, with γ-tubulin for normalization (right panel). N=2 different 
experiments for each strain. (C and D) Indicated HDF strains were treated 
with Nutlin-3a (10 μM) or DMSO vehicle alone for 48 hours. CSL mRNA (C) 
and CSL and p53 protein (D) levels were assessed as in A and B, 
respectively. N=2 different experiments for each strain. (E and F) HDFs were 
treated with Nutlin-3a (10 μM) or DMSO vehicle for the indicated time points. 
CSL and p53 protein (E) and p21 mRNA (F) levels were assessed as in B and 
A, respectively. (G and H) Indicated strains of HDFs infected with control 
(CTRL) versus p53 silencing (shp53) retroviruses were analyzed for CSL 
mRNA and protein levels as in A and B respectively. N=2 for Fb79 and Fb80. 
* p < 0.0001, ** p=0.0003. 
 
Fig. 4. p53 controls CSL expression via multiple mechanisms. (A) Map of 
the entire CSL locus showing the transcribed region (green bar), transcription 
start sites (TSS1 and 2) and exons (E1-E11) and, below, localization of 
insulators (blue), promoters (red) and enhancers (yellow) as predicted for 
human primary fibroblasts on the basis of the ENCODE data base (as 
detailed in Materials and Methods). (B) Graphic illustrations of ChIP-seq 
analysis of p53-binding peaks in the CDKN1A, CSL, and PTK2 loci in HDFs 
treated with Nutlin-3a (10 μM for 48 hours) or DMSO control (magenta and 
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blue colors, respectively). P53 binding peaks induced by Nutlin-3a treatment 
are highlighted (red boxes). A full list of p53-binding peaks is provided 
in Supplementary Table 2. (C) Top: Map of the 1.94 kb CSL promoter region 
with predicted p53 recognition sequences (blue boxes) and corresponding 
primers used for the ChIP experiments (magenta arrows) and adjacent exons 
(green boxes). Bottom: ChIP assay of p53 binding to the CSL promoter and 
the CSL exon 4 region in HDFs treated for 48 hours with Nutlin-3a (10 μM) or 
DMSO control. Binding enrichment to a upstream CSL region devoid of p53 
recognition sequences was used as negative control (negative CTRL), while 
binding to a p53 binding site in the CDKN1A promoter (chr6: 36,644,111-
36,644,216) was used as positive control. (D) HDFs were co-transfected in 
triplicate wells with a luciferase reporter construct with the CSL promoter 
(CSLpr-1.94kb) region shown in the map in (C), with either the G/G or the A/A 
alleles for the rs7657866 SNP, together with increasing amounts of a plasmid 
over-expressing p53. Luciferase activity was measured 30 h later, using 
Renilla internal control for normalization. Shown are results of 2 independent 
experiments (Exp. 1 and 2). (E) HDFs (Fb79) stably infected with lentiviruses 
for doxycycline-inducible p21 expression were treated or not with doxycycline 
for 48 hours and CSL mRNA levels measured by RT-qPCR using 36β4 for 
normalization. N=3 independent experiments. (F) HDFs (Fb79) were used for 
immunoblotting with CSL and p53 antibodies using γ-tubulin as equal loading 
control. CSL and γ-tubulin blots were performed by sequential blotting of the 
same membrane without stripping (left panel). Relative protein levels were 
quantified using the ImageStudio program, with γ-tubulin for normalization 
(right panel). Representative of 2 independent experiments. (G) Summary 
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diagram of the reciprocal negative regulation of CSL and p53 expression and 
activity, respectively. As discussed in the text, in response to acute 
genotoxic/oxidative stress, such as UVA or ROS, p53 is activated and 
represses CSL, which is in turn not longer able to lessen p53 activity. Thus, 
CSL down-modulation allows for full p53 activation. * p < 0.0001, ** p=0.0002, 
*** p=0.0006, # p=0.0089, ## p=0.0228, °= 0.0024. 
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Supplementary Figure 1. P53 is not the main effector of UVA-induced 
CSL downregulation. (A,B) Human dermal fibroblasts (HDFs) stably infected 
with shRNA retroviruses against p53 in parallel with control viruses were 
irradiated with 1J/cm2 of UVA, collected at the indicated time points and CSL 
(A), p53 and CDKN1A (B) mRNA levels were measured by RT-qPCR using 
36β4 for normalization. (C) HDFs were treated with 1J/cm2 UVA, collected at 
the indicated time points and CSL and NOTCH2 mRNA levels were measured 
by RT-qPCR using 36β4 for normalization. 
